Company News

 

July 23, 2002

Public Relations
Ono Pharmaceutical Co., Ltd.
Tel: +81-6-6222-5551
Fax: +81-6-6222-2875


Announcement of Manufacturing Approval for Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Kimiichiro Matsumoto) announces that manufacturing of Onoact® 50 for injection, the drug for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia), was approved on July 5, 2002.

During operation, various stimulative actions on a living body, such as endotracheal intubation, extubation, skin incision and other surgical procedures, facilitate the excessive discharge of catecholamine mainly from the sympathetic nerve, leading to an increase in heart rate, as well as tachyarrhythmia.

Especially in patients with ischemic heart disease and/or hypertension, even a slightly increased heart rate may constitute an additional burden on the heart, and induce ischemia at cardiac coronary artery etc. Therefore, the development of a drug that can be easily titrated for emergency treatment of intraoperative tachyarrhythmia has long been awaited.

Onoact® 50 for injection, which has been developed to fulfill these medical needs, improves tachyarrhythmia by selectively blocking β1 receptors located chiefly in the heart, and by inhibiting the action of catecholamine that raises the heart rate.

Unlike conventional β blockers, Onoact® 50 for injection can be used in emergency treatment of intraoperative tachyarrhythmia, because this fast-acting drug can be easily titrated for its very short half-life in blood (approx. 4 min). With these features, Onoact® 50 for injection is attracting attention as an innovative drug.


      Product Profile of Onoact® 50 for Injection


     Nonproprietary name : Landiolol hydrochloride

     Active ingredient : 50 mg landiolol hydrochloride per vial

     Indications : Emergency treatment for intraoperative tachyarrhythmia (atrial fibrillation, atrial flutter and sinus tachycardia)

     Dosage and administration : Landiolol hydrochloride is intravenously administered at 0.125 mg/kg/min for one minute, and at 0.04 mg/kg/min thereafter. The dosage should be appropriately adjusted between 0.01 and 0.04 mg/kg/min, based on the heart rate and blood pressure to be measured during the infusion.

     Manufactured and distributed by : Ono Pharmaceutical Co., Ltd.